Psoriatic Nails

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 138 Experts worldwide ranked by ideXlab platform

Dimitris Rigopoulos - One of the best experts on this subject based on the ideXlab platform.

  • Treatment of Psoriatic Nails with Tazarotene Cream 0.1% vs. Clobetasol Propionate 0.05% Cream: A Double-blind Study
    Acta Dermato-venereologica, 2020
    Co-Authors: Dimitris Rigopoulos, Stamatis Gregoriou, Andreas Katsambas
    Abstract:

    t azarotene 1.13 (0.88) 0.28 (0.45) 0.97 (0.71) Clobetasol 1.09 (0.99) 0.36 (0.48) 0.97 (0.85) Onycholysis t azarotene 1.97 (1.27) 0.82 (0.73) 1.54 (1.00) Clobetasol 1.90 (1.28) 0.82 (0.62) 1.73 (1.09) Hyperkeratosis t azarotene 1.80 (1.04) 0.36 (0.48) 0.97 (0.80) Clobetasol 1.70 (0.95) 0.58 (0.66) 1.56 (0.83) Salmon patches t azarotene 1.15 (0.89) 0.17 (0.38) 0.69 (0.72) Clobetasol 1.07 (0.78) 0.19 (0.45) 0.85 (0.61)

  • evaluation of the efficacy and safety of infliximab on Psoriatic Nails an unblinded nonrandomized open label study
    British Journal of Dermatology, 2008
    Co-Authors: Dimitris Rigopoulos, Stamatis Gregoriou, A Stratigos, George Larios, Chrysovalantis Korfitis, D Papaioannou, Christina Antoniou, D Ioannides
    Abstract:

    Summary Background  Despite advances in the treatment of skin psoriasis during the last years, therapy of Psoriatic Nails remains a challenge. Objectives  The objective of this unblended, nonrandomized, open-label study was to evaluate the efficacy and safety of infliximab on nail psoriasis. Patients/Methods  Eighteen Psoriatic patients with nail involvement, consecutively selected among patients scheduled to start infliximab infusions were included in the study. Thirteen of these patients had Psoriatic arthritis and five had severe plaque type psoriasis. Outcome measures were assessed at baseline and at weeks 14, 22, 30 and 38 using the nail psoriasis severity index (NAPSI). Patients also filled in a Greek translation of the international onychomycosis-specific questionnaire to assess improvement in quality of life after improvement of Psoriatic nail signs. Results  All 18 patients completed the study. Significant improvement was noted in most patients after the third infusion as shown by the reduction of mean NAPSI (NAPSIm) from 55·8 at baseline to 29·8 at week 14. Evaluation after six infusions, at week 38, showed an almost complete resolution of Psoriatic nail involvement (NAPSIm: 3·3). No adverse event was observed. All patients reported satisfaction with the results and significant improvement in their quality of life with reduction of the score of the international quality of life questionnaire from 66·3 at baseline to 19·1 at week 38. Conclusions  Αlthough there is no control group, this data suggests that infliximab is effective for Psoriatic nail disease in the context of severe skin and joint involvement.

  • Evaluation of the efficacy and safety of infliximab on Psoriatic Nails: an unblinded, nonrandomized, open‐label study
    British Journal of Dermatology, 2008
    Co-Authors: Dimitris Rigopoulos, Stamatis Gregoriou, A Stratigos, George Larios, Chrysovalantis Korfitis, D Papaioannou, Christina Antoniou, D Ioannides
    Abstract:

    Summary Background  Despite advances in the treatment of skin psoriasis during the last years, therapy of Psoriatic Nails remains a challenge. Objectives  The objective of this unblended, nonrandomized, open-label study was to evaluate the efficacy and safety of infliximab on nail psoriasis. Patients/Methods  Eighteen Psoriatic patients with nail involvement, consecutively selected among patients scheduled to start infliximab infusions were included in the study. Thirteen of these patients had Psoriatic arthritis and five had severe plaque type psoriasis. Outcome measures were assessed at baseline and at weeks 14, 22, 30 and 38 using the nail psoriasis severity index (NAPSI). Patients also filled in a Greek translation of the international onychomycosis-specific questionnaire to assess improvement in quality of life after improvement of Psoriatic nail signs. Results  All 18 patients completed the study. Significant improvement was noted in most patients after the third infusion as shown by the reduction of mean NAPSI (NAPSIm) from 55·8 at baseline to 29·8 at week 14. Evaluation after six infusions, at week 38, showed an almost complete resolution of Psoriatic nail involvement (NAPSIm: 3·3). No adverse event was observed. All patients reported satisfaction with the results and significant improvement in their quality of life with reduction of the score of the international quality of life questionnaire from 66·3 at baseline to 19·1 at week 38. Conclusions  Αlthough there is no control group, this data suggests that infliximab is effective for Psoriatic nail disease in the context of severe skin and joint involvement.

  • treatment of Psoriatic Nails with tazarotene cream 0 1 vs clobetasol propionate 0 05 cream a double blind study
    Acta Dermato-venereologica, 2007
    Co-Authors: Dimitris Rigopoulos, Stamatis Gregoriou, Andreas Katsambas
    Abstract:

    t azarotene 1.13 (0.88) 0.28 (0.45) 0.97 (0.71) Clobetasol 1.09 (0.99) 0.36 (0.48) 0.97 (0.85) Onycholysis t azarotene 1.97 (1.27) 0.82 (0.73) 1.54 (1.00) Clobetasol 1.90 (1.28) 0.82 (0.62) 1.73 (1.09) Hyperkeratosis t azarotene 1.80 (1.04) 0.36 (0.48) 0.97 (0.80) Clobetasol 1.70 (0.95) 0.58 (0.66) 1.56 (0.83) Salmon patches t azarotene 1.15 (0.89) 0.17 (0.38) 0.69 (0.72) Clobetasol 1.07 (0.78) 0.19 (0.45) 0.85 (0.61)

D Ioannides - One of the best experts on this subject based on the ideXlab platform.

  • evaluation of the efficacy and safety of infliximab on Psoriatic Nails an unblinded nonrandomized open label study
    British Journal of Dermatology, 2008
    Co-Authors: Dimitris Rigopoulos, Stamatis Gregoriou, A Stratigos, George Larios, Chrysovalantis Korfitis, D Papaioannou, Christina Antoniou, D Ioannides
    Abstract:

    Summary Background  Despite advances in the treatment of skin psoriasis during the last years, therapy of Psoriatic Nails remains a challenge. Objectives  The objective of this unblended, nonrandomized, open-label study was to evaluate the efficacy and safety of infliximab on nail psoriasis. Patients/Methods  Eighteen Psoriatic patients with nail involvement, consecutively selected among patients scheduled to start infliximab infusions were included in the study. Thirteen of these patients had Psoriatic arthritis and five had severe plaque type psoriasis. Outcome measures were assessed at baseline and at weeks 14, 22, 30 and 38 using the nail psoriasis severity index (NAPSI). Patients also filled in a Greek translation of the international onychomycosis-specific questionnaire to assess improvement in quality of life after improvement of Psoriatic nail signs. Results  All 18 patients completed the study. Significant improvement was noted in most patients after the third infusion as shown by the reduction of mean NAPSI (NAPSIm) from 55·8 at baseline to 29·8 at week 14. Evaluation after six infusions, at week 38, showed an almost complete resolution of Psoriatic nail involvement (NAPSIm: 3·3). No adverse event was observed. All patients reported satisfaction with the results and significant improvement in their quality of life with reduction of the score of the international quality of life questionnaire from 66·3 at baseline to 19·1 at week 38. Conclusions  Αlthough there is no control group, this data suggests that infliximab is effective for Psoriatic nail disease in the context of severe skin and joint involvement.

  • Evaluation of the efficacy and safety of infliximab on Psoriatic Nails: an unblinded, nonrandomized, open‐label study
    British Journal of Dermatology, 2008
    Co-Authors: Dimitris Rigopoulos, Stamatis Gregoriou, A Stratigos, George Larios, Chrysovalantis Korfitis, D Papaioannou, Christina Antoniou, D Ioannides
    Abstract:

    Summary Background  Despite advances in the treatment of skin psoriasis during the last years, therapy of Psoriatic Nails remains a challenge. Objectives  The objective of this unblended, nonrandomized, open-label study was to evaluate the efficacy and safety of infliximab on nail psoriasis. Patients/Methods  Eighteen Psoriatic patients with nail involvement, consecutively selected among patients scheduled to start infliximab infusions were included in the study. Thirteen of these patients had Psoriatic arthritis and five had severe plaque type psoriasis. Outcome measures were assessed at baseline and at weeks 14, 22, 30 and 38 using the nail psoriasis severity index (NAPSI). Patients also filled in a Greek translation of the international onychomycosis-specific questionnaire to assess improvement in quality of life after improvement of Psoriatic nail signs. Results  All 18 patients completed the study. Significant improvement was noted in most patients after the third infusion as shown by the reduction of mean NAPSI (NAPSIm) from 55·8 at baseline to 29·8 at week 14. Evaluation after six infusions, at week 38, showed an almost complete resolution of Psoriatic nail involvement (NAPSIm: 3·3). No adverse event was observed. All patients reported satisfaction with the results and significant improvement in their quality of life with reduction of the score of the international quality of life questionnaire from 66·3 at baseline to 19·1 at week 38. Conclusions  Αlthough there is no control group, this data suggests that infliximab is effective for Psoriatic nail disease in the context of severe skin and joint involvement.

Stamatis Gregoriou - One of the best experts on this subject based on the ideXlab platform.

  • Treatment of Psoriatic Nails with Tazarotene Cream 0.1% vs. Clobetasol Propionate 0.05% Cream: A Double-blind Study
    Acta Dermato-venereologica, 2020
    Co-Authors: Dimitris Rigopoulos, Stamatis Gregoriou, Andreas Katsambas
    Abstract:

    t azarotene 1.13 (0.88) 0.28 (0.45) 0.97 (0.71) Clobetasol 1.09 (0.99) 0.36 (0.48) 0.97 (0.85) Onycholysis t azarotene 1.97 (1.27) 0.82 (0.73) 1.54 (1.00) Clobetasol 1.90 (1.28) 0.82 (0.62) 1.73 (1.09) Hyperkeratosis t azarotene 1.80 (1.04) 0.36 (0.48) 0.97 (0.80) Clobetasol 1.70 (0.95) 0.58 (0.66) 1.56 (0.83) Salmon patches t azarotene 1.15 (0.89) 0.17 (0.38) 0.69 (0.72) Clobetasol 1.07 (0.78) 0.19 (0.45) 0.85 (0.61)

  • evaluation of the efficacy and safety of infliximab on Psoriatic Nails an unblinded nonrandomized open label study
    British Journal of Dermatology, 2008
    Co-Authors: Dimitris Rigopoulos, Stamatis Gregoriou, A Stratigos, George Larios, Chrysovalantis Korfitis, D Papaioannou, Christina Antoniou, D Ioannides
    Abstract:

    Summary Background  Despite advances in the treatment of skin psoriasis during the last years, therapy of Psoriatic Nails remains a challenge. Objectives  The objective of this unblended, nonrandomized, open-label study was to evaluate the efficacy and safety of infliximab on nail psoriasis. Patients/Methods  Eighteen Psoriatic patients with nail involvement, consecutively selected among patients scheduled to start infliximab infusions were included in the study. Thirteen of these patients had Psoriatic arthritis and five had severe plaque type psoriasis. Outcome measures were assessed at baseline and at weeks 14, 22, 30 and 38 using the nail psoriasis severity index (NAPSI). Patients also filled in a Greek translation of the international onychomycosis-specific questionnaire to assess improvement in quality of life after improvement of Psoriatic nail signs. Results  All 18 patients completed the study. Significant improvement was noted in most patients after the third infusion as shown by the reduction of mean NAPSI (NAPSIm) from 55·8 at baseline to 29·8 at week 14. Evaluation after six infusions, at week 38, showed an almost complete resolution of Psoriatic nail involvement (NAPSIm: 3·3). No adverse event was observed. All patients reported satisfaction with the results and significant improvement in their quality of life with reduction of the score of the international quality of life questionnaire from 66·3 at baseline to 19·1 at week 38. Conclusions  Αlthough there is no control group, this data suggests that infliximab is effective for Psoriatic nail disease in the context of severe skin and joint involvement.

  • Evaluation of the efficacy and safety of infliximab on Psoriatic Nails: an unblinded, nonrandomized, open‐label study
    British Journal of Dermatology, 2008
    Co-Authors: Dimitris Rigopoulos, Stamatis Gregoriou, A Stratigos, George Larios, Chrysovalantis Korfitis, D Papaioannou, Christina Antoniou, D Ioannides
    Abstract:

    Summary Background  Despite advances in the treatment of skin psoriasis during the last years, therapy of Psoriatic Nails remains a challenge. Objectives  The objective of this unblended, nonrandomized, open-label study was to evaluate the efficacy and safety of infliximab on nail psoriasis. Patients/Methods  Eighteen Psoriatic patients with nail involvement, consecutively selected among patients scheduled to start infliximab infusions were included in the study. Thirteen of these patients had Psoriatic arthritis and five had severe plaque type psoriasis. Outcome measures were assessed at baseline and at weeks 14, 22, 30 and 38 using the nail psoriasis severity index (NAPSI). Patients also filled in a Greek translation of the international onychomycosis-specific questionnaire to assess improvement in quality of life after improvement of Psoriatic nail signs. Results  All 18 patients completed the study. Significant improvement was noted in most patients after the third infusion as shown by the reduction of mean NAPSI (NAPSIm) from 55·8 at baseline to 29·8 at week 14. Evaluation after six infusions, at week 38, showed an almost complete resolution of Psoriatic nail involvement (NAPSIm: 3·3). No adverse event was observed. All patients reported satisfaction with the results and significant improvement in their quality of life with reduction of the score of the international quality of life questionnaire from 66·3 at baseline to 19·1 at week 38. Conclusions  Αlthough there is no control group, this data suggests that infliximab is effective for Psoriatic nail disease in the context of severe skin and joint involvement.

  • treatment of Psoriatic Nails with tazarotene cream 0 1 vs clobetasol propionate 0 05 cream a double blind study
    Acta Dermato-venereologica, 2007
    Co-Authors: Dimitris Rigopoulos, Stamatis Gregoriou, Andreas Katsambas
    Abstract:

    t azarotene 1.13 (0.88) 0.28 (0.45) 0.97 (0.71) Clobetasol 1.09 (0.99) 0.36 (0.48) 0.97 (0.85) Onycholysis t azarotene 1.97 (1.27) 0.82 (0.73) 1.54 (1.00) Clobetasol 1.90 (1.28) 0.82 (0.62) 1.73 (1.09) Hyperkeratosis t azarotene 1.80 (1.04) 0.36 (0.48) 0.97 (0.80) Clobetasol 1.70 (0.95) 0.58 (0.66) 1.56 (0.83) Salmon patches t azarotene 1.15 (0.89) 0.17 (0.38) 0.69 (0.72) Clobetasol 1.07 (0.78) 0.19 (0.45) 0.85 (0.61)

Eva Szepes - One of the best experts on this subject based on the ideXlab platform.

  • mykotische infektionen psoriatischer nagel mycotic infections of Psoriatic Nails
    Mycoses, 2009
    Co-Authors: Eva Szepes
    Abstract:

    Zusammenfassung: Die Verfasserin untersuchte das Vorkommen mykotischer Infektionen von Psoriasis-Nageln. Die Ergebnisse wurden mit den Quoten des Pilznachweises bei primarer Onychomykose verglichen. Bei Nagelpsoriasis ist die Haufigkeit von Dermatophyten-Infektionen geringer, dagegen das Vorkommen von Sprospilzbesiedlung hoher als bei primaren Onychomykosen. Summary: Mycotic infections of Psoriatic Nails were investigated. The cultural results were compared with the distribution of the pathogens found in primary onychomycosis. In Psoriatic Nails the rate of dermatophytic infections was lower and the frequency of yeast infections higher than in primary onychomycosis.

  • Mykotische Infektionen psoriatischer Nägel/Mycotic Infections of Psoriatic Nails
    Mycoses, 2009
    Co-Authors: Eva Szepes
    Abstract:

    Zusammenfassung: Die Verfasserin untersuchte das Vorkommen mykotischer Infektionen von Psoriasis-Nageln. Die Ergebnisse wurden mit den Quoten des Pilznachweises bei primarer Onychomykose verglichen. Bei Nagelpsoriasis ist die Haufigkeit von Dermatophyten-Infektionen geringer, dagegen das Vorkommen von Sprospilzbesiedlung hoher als bei primaren Onychomykosen. Summary: Mycotic infections of Psoriatic Nails were investigated. The cultural results were compared with the distribution of the pathogens found in primary onychomycosis. In Psoriatic Nails the rate of dermatophytic infections was lower and the frequency of yeast infections higher than in primary onychomycosis.

Andreas Katsambas - One of the best experts on this subject based on the ideXlab platform.

Related terms

Psoriatic Nails - 15 days free trial to Access Experts & Abstracts